Efficacy of a Fibrin Sealant in Burn Surgery
Primary Purpose
Burns
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Tisseel Fibrin Sealant
Sponsored by
About this trial
This is an interventional treatment trial for Burns focused on measuring burns, hemostasis, skin graft, Surgical Hemostasis, Grafting, Skin
Eligibility Criteria
Inclusion Criteria: Requires skin grafting of an acute or reconstructive burn wound. Exclusion Criteria: Active disseminated intravascular coagulation (DIC) or known hypersensitivity to bovine protein.
Sites / Locations
- Shriners Burns Hospital
Outcomes
Primary Outcome Measures
initial wound hemostasis
initial donor site hemostasis
initial graft fixation
percent graft take at 1 week
outcome and cosmetic appearance at routine intervals up to 24 months
Secondary Outcome Measures
Full Information
NCT ID
NCT00181974
First Posted
September 14, 2005
Last Updated
October 22, 2012
Sponsor
Massachusetts General Hospital
Collaborators
Shriners Hospitals for Children
1. Study Identification
Unique Protocol Identification Number
NCT00181974
Brief Title
Efficacy of a Fibrin Sealant in Burn Surgery
Official Title
Efficacy of a Fibrin Sealant in Burn Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
October 2012
Overall Recruitment Status
Completed
Study Start Date
March 2000 (undefined)
Primary Completion Date
February 2007 (Actual)
Study Completion Date
November 2007 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital
Collaborators
Shriners Hospitals for Children
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to determine the effectiveness of a fibrin glue in burn surgery with respect to hemostasis and skin graft fixation.
Detailed Description
Burn patients require extensive split-thickness skin grafting operations. These operations necessitate excision of burn wounds and the procurement of autografts. Both of these result in bleeding open wounds. Fibrin sealants may be of benefit in three aspects of burn surgery:
as a hemostatic agent on excised burns,
as a hemostatic agent on donor sites, and
as a method of fixation of skin grafts to wounds.
Skin grafts are routinely secured with surgical staples. Patients with large burns will commonly have hundreds, even thousands of staples used during the course of their care. Problems associated with the use of surgical staples include:
discomfort upon removal and
staples become deeply embedded in the tissue.
If effective in securing skin grafts, fibrin glue would directly benefit burn patients by decreasing the number of staples required, and thereby decreasing the number of retained staples. Fibrin sealant is produced from human fibrinogen and human thrombin from pooled plasma that is virally inactivated by a two-stage heating process.
Subjects will serve as their own control. They will have an area of their wound treated with the fibrin sealant and another area treated with the standard of care. Both areas will be compared for hemostasis, skin graft fixation, wound healing, and cosmetic outcome.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Burns
Keywords
burns, hemostasis, skin graft, Surgical Hemostasis, Grafting, Skin
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
25 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Tisseel Fibrin Sealant
Primary Outcome Measure Information:
Title
initial wound hemostasis
Title
initial donor site hemostasis
Title
initial graft fixation
Title
percent graft take at 1 week
Title
outcome and cosmetic appearance at routine intervals up to 24 months
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Requires skin grafting of an acute or reconstructive burn wound.
Exclusion Criteria:
Active disseminated intravascular coagulation (DIC) or known hypersensitivity to bovine protein.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert L Sheridan, M.D.
Organizational Affiliation
Shriners Burns Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Shriners Burns Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Efficacy of a Fibrin Sealant in Burn Surgery
We'll reach out to this number within 24 hrs